Journal: bioRxiv
Article Title: Pharmacological PINK1 activation ameliorates Pathology in Parkinson’s Disease models
doi: 10.1101/2023.02.14.528378
Figure Lengend Snippet: (A) Related to . Immunostaining shows representative images of neurons treated with mPFFs and 2.8 µM MTK458. Primary hippocampal neurons were seeded for immunostaining, treated with mPFFs (0.5 µg/mL) and MTK458 as in (E), and on DIV14 fixed for immunostaining with antibodies against pS129 α-syn, NfH and TUJ1. Scale bar, 50 µm. (B) Mice were challenged with striatal injection of PFFs of PBS. After 2 weeks, ipsilateral or contralateral striatum brain pieces were harvested for sequential extraction with buffers containing increasing amounts of detergent. NP-40 insoluble fractions were analyzed by immunoblot. (C-D) Quantification of (B) is shown. (E-G) Mice were challenged with striatal injection of PBS or PFF, and then dosed with MTK458 for 6 months. Mice were analyzed for TREM2 in the ipsilateral striatum (E), plasma CXCL1 (F), and plasma IL-6 (G) levels. (H) Similar experiment to , except that mice were sacrificed 180 days after PFF injection and MTK458 dosing (QD, PO) at the indicated concentrations. (I-J) Quantification of (H) is shown. Mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p<0.0001, n.s., not significant.
Article Snippet: Sheep anti-TREM2 polyclonal antibody (R&D systems BAF1729) was coated onto Small Spot Streptavidin 96 well plates (MSD, L45SA-2) as the capture antibody.
Techniques: Immunostaining, Injection, Extraction, Western Blot, Clinical Proteomics